Tag:

India

Latest Headlines

Latest Headlines

Are price caps contributing to drug shortages in India?

Indian pharmacies are reporting shortages of a number of drugs which are on the country's essential medications list and believe price caps are to blame.

Biocon to build new plant in Vizag, India

Biocon intends to build a new facility in Vizag, India, for manufacturing insulin products. It is a turnabout for the Indian company, which went to Malaysia with its first insulin facility, in part, over concerns that India was falling behind in providing dependable infrastructure to the pharma industry.

Stada, Dr. Reddy's and others dodge German drug suspensions with appeals

A host of drugmakers will not have to pull from the market, at least for now, generic drugs that German regulators say are suspect. The companies have bought some time with appeals of a decision by regulators to nix sales of dozens of medications because of flaws in clinical trials handled by an Indian contractor.

Bayer fails last-ditch attempt to block India's cheap Nexavar copies

Bayer was dealt a crushing blow in its ongoing fight to block generic sales of its cancer powerhouse Nexavar in India, as the country's Supreme Court ruled that an Indian generics group had the right to sell a copycat version of the drug.

India's NPPA extends pricing policy on drugs, adding fuel to price cap fire

Amid escalating tension between Big Pharma and India's National Pharmaceutical Pricing Authority over price caps on "essential drugs," the NPPA has extended its pricing policies to cover 52 additional meds, including commonly used painkillers and antibiotics and drugs for cancer and skin disease treatment.

Indian drugmakers lambast proposed PET packaging ban

Indian drugmakers are in a dogfight with Indian regulators who have proposed banning the use of PET plastic bottles for some drug packaging. If they have to move to glass, it will add up to 30% to their transportation cost per bottle, they have complained.

Sun and Ranbaxy must sell off urology drugs in India for deal approval

Antitrust regulators in India have approved the $4 billion sale of Ranbaxy Laboratories to Sun Pharmaceutical on the condition the two companies divest 7 products to avoid market concentration, Bloomberg reports.

EU nations yank drugs over GVK data scandal

Some European Union states have suspended the approvals of drugs tied to a data falsification scandal at CRO GVK Biosciences, and the European Medicines Agency is investigating whether to recommend a continental halt.

India wants in on the biotech hub trend

India should take a cue from the biotech hotbeds of the U.S. and U.K., a local trade groups says, investing in infrastructure to help foster startups and grow innovation clusters of its own.

Some Indian drugmakers routinely toss out bad test results: Bloomberg

At least a dozen drugmakers with operations in India were accused by the FDA last year of routinely throwing out negative test results of bad batches of pharmaceuticals, some of which eventually made it to U.S. consumers.